← Back to patent-cliff list
APG-157
Tier C — Watch / tradeAPG-157
Aveta Biomics
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：Not applicable
Indications (approved)：口腔癌, Oral squamous cell carcinoma, 口咽部鳞状细胞癌, Head and neck cancer, Head and neck squamous cell carcinoma, Glioma, Glioblastoma, 口腔畸形
Regional status
US
Phase II
2022-04-22
EU
-
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of APG-157?
Approved indications include: 口腔癌, Oral squamous cell carcinoma, 口咽部鳞状细胞癌, Head and neck cancer, Head and neck squamous cell carcinoma, Glioma, Glioblastoma, 口腔畸形.
When does the APG-157 patent expire?
No public expiry year is available for APG-157 yet; this page updates once verified.
How do I get a quote for APG-157 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-29